Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith DrugsNSE:ZENITHDRUG +1.80%36 Days Payable is 123.39 as of Mar. 2026, which is 22% below its 10-year median of 157.70. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 36/100. The stock has 8 warning signs investors should review. Among 925 Drug Manufacturers companies, Zenith Drugs ranks better than 69.84% on this metric.
The historical rank and industry rank for Zenith Drugs's Days Payable or its related term are showing as below:
NSE:ZENITHDRUG'
s Days Payable Range Over the Past 10 Years
Min: 131.37 Med: 157.7 Max: 183.42
Current: 131.37
During the past 6 years, Zenith Drugs's highest Days Payable was 183.42. The lowest was 131.37. And the median was 157.70.
NSE:ZENITHDRUG's Days Payable is ranked better than 69.84% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:ZENITHDRUG: 131.37
Zenith Drugs's Days Payable
declined
from Mar. 2025 (179.66) to Mar. 2026 (123.39).
It may suggest that Zenith Drugsaccelerated paying its suppliers.
Zenith Drugs Days Payable Related Terms
Zenith Drugs Days Payable Historical Data
* Premium members only.
The historical data trend for Zenith Drugs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ZENITHDRUG vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Drugs Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's Days Payable distribution charts can be found below:
* The bar in red indicates where Zenith Drugs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zenith Drugs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Drugs (NSE:ZENITHDRUG) has a Days Payable of 123.39 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zenith Drugs and its competitors. This is 22% below median its historical median of 157.70. Over the past decade, Zenith Drugs' Days Payable has ranged from 131.37 to 183.42. According to the industry distribution chart, Zenith Drugs ranks #279 out of 925 companies in the Drug Manufacturers industry, placing it in the top 30.2%.
Is Zenith Drugs' Days Payable too high?
Zenith Drugs' current Days Payable of 123.39 is 22% below median its 10-year median of 157.70. Over the past 10 years, this metric has ranged from a low of 131.37 to a high of 183.42. The Drug Manufacturers industry median Days Payable is 90.38. Zenith Drugs' value of 123.39 is 36.5% above this industry median. Based on the distribution chart, Zenith Drugs ranks #279 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zenith Drugs has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #279 out of 925 companies for Days Payable. This puts Zenith Drugs in the upper half of its industry. The industry median Days Payable is 90.38. Zenith Drugs' value of 123.39 is 36.5% above this benchmark. Historically, Zenith Drugs' own Days Payable has ranged from 131.37 to 183.42 over the past decade. While the company's 10-year median is 157.70 vs. the industry median of 90.38, Zenith Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Drugs's current Days Payable of 123.39 is 36.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zenith Drugs and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current Days Payable is 123.39, which is 22% below median its own 10-year median of 157.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Days Payable of 123.39. The current Days Payable is 123.39, which is 22% below median its 10-year median of 157.70 and 36.5% above the Drug Manufacturers industry median of 90.38. Zenith Drugs' overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Days Payable is 123.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
36GF Score
Get the complete analysis for NSE:ZENITHDRUG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
